Letybo (Botulinum Toxin Type A)

Letybo, a botulinum toxin type A preparation, is indicated for several neuromuscular and hypersecretory conditions.

• Cervical dystonia: reduces abnormal neck muscle contractions and improves head posture.
• Blepharospasm: relaxes overactive eyelid muscles to lessen involuntary blinking.
• Chronic migraine: decreases frequency of migraine attacks when injected in specific head muscles.
• Upper limb spasticity: lessens muscle stiffness and improves range of motion in post‑stroke patients.
• Primary axillary hyperhidrosis: diminishes excessive sweating by inhibiting sweat gland activity.

• Botulinum toxin type A is a neurotoxin that cleaves SNAP‑25, a protein essential for the fusion of acetylcholine‑containing vesicles with the presynaptic membrane at the neuromuscular junction. By preventing acetylcholine release, it produces a reversible chemical denervation that results in temporary muscle paralysis and reduced glandular secretion.

Injection of Letybo may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Bruising: localized discoloration due to minor bleeding.
• Headache: transient headache following administration.
• Localized muscle weakness: temporary reduction in strength near the injection area.
• Dry mouth: reduced salivation.
• Flu‑like symptoms: mild fever, fatigue or malaise.

Serious or Rare Side Effects

• Dysphagia: difficulty swallowing that may require medical attention.
• Respiratory compromise: breathing difficulties due to spread of paralysis.
• Allergic reaction: rash, itching, swelling or anaphylaxis.
• Botulism‑like systemic spread: generalized muscle weakness beyond the injection site.
• Vision changes: blurred vision or double vision.
• Urinary retention: difficulty emptying the bladder.

Before prescribing Letybo, clinicians should consider several precautionary measures to ensure patient safety.

• Pregnancy: safety not established; avoid unless potential benefit justifies the risk.
• Breastfeeding: unknown effects; weigh benefits against possible infant exposure.
• Neuromuscular disorders: use with caution in patients with myasthenia gravis or Lambert‑Eaton syndrome.
• Concomitant aminoglycoside antibiotics or other neuromuscular blocking agents: monitor for enhanced muscle weakness.
• Known hypersensitivity: do not administer to patients with a documented allergy to botulinum toxin or any formulation component.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo can interact with other medicines, influencing its safety or efficacy.

Major Interactions (Avoid)

• Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade.
• Other botulinum toxin products: increased risk of systemic spread and toxicity.
• Neuromuscular blocking agents used during anesthesia: heightened risk of prolonged paralysis.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs (e.g., atropine): may modify therapeutic response.
• Calcium channel blockers (e.g., verapamil): possible additive effect on muscle weakness.
• Anticoagulants (e.g., warfarin): may increase bruising at injection sites.